Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: Omadacycline, Linezolid; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more

Conditions: Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions: PhXA41, timolol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Reproductive Sterilization
Interventions: Adiana Transcervical Sterilization System; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Roseville, California • San Rafael, California + 11 more

Conditions: Pulmonary Arterial Hypertension
Interventions: AV-101; Drug
Lead sponsor: Aerovate Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Psoriasis
Interventions: placebo, CT 327; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Orange, California • Palo Alto, California • Santa Rosa, California + 4 more

Conditions: Acne Vulgaris
Interventions: Visonac PDT, Vehicle cream with PDT; Drug
Lead sponsor: Photocure; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Palbociclib, Carboplatin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Generalized Myasthenia Gravis
Interventions: YTB323; Genetic
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Progressive Supranuclear Palsy
Interventions: BIIB092, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Iodine I 131 Tositumomab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 6
States / cities: Bay Pines, Florida • Chicago, Illinois • Ann Arbor, Michigan + 3 more

Conditions: Spondylosis, Cervical Spondylosis, Spondylolisthesis, Herniated Nucleus Pulposus, Degenerative Disc Disease
Interventions: ViBone; Other
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: San Diego, California • Danbury, Connecticut • Annapolis, Maryland + 1 more

Conditions: Parkinson Disease, Multiple Sclerosis, Stroke
Interventions: Low-Fidelity PDS, High Fidelity Fixed-Base Simulator; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 25 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Lymphatic Disease, HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Soft Tissue Sarcoma
Interventions: ADI PEG20, Placebo; Drug · Other
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Loma Linda, California • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: COVID-19 Pandemic
Interventions: Diagnostic Test: IN Vitro; Diagnostic Test
Lead sponsor: 3EO Health; Industry
Eligibility: 2 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Humble, Texas • Kingwood, Texas

Conditions: Skin Quality
Interventions: Secret RF; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Major Depressive Disorder
Interventions: Quetiapine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 66 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • Fort Myers, Florida + 10 more

Conditions: Neuroendocrine Tumors in Lung
Interventions: Lanreotide (Autogel formulation), Placebo, Best Supportive Care; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
Interventions: ET140203 autologous T cell product; Biological
Lead sponsor: Eureka Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Duarte, California • Westwood, Kansas

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Search by objective public record fields.

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

CT 327 in the Treatment of Psoriasis Vulgaris

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

ViBone in Cervical and Lumbar Spine Fusion

User-friendliness of a Portable Driving Simulator

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults

COVID-19 Molecular OTC At Home Test

Multi-Center, Clinical Evaluation of the Cutera Secret RF Device

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia